CorMedix Inc (CRMD NASDAQ) stock market data APIs
$4.6451
0.27(5.8%)
as of November 13, 2026
Try our APIs with
free plan!
CorMedix Inc Financial Data Overview
Price chart is built with
Anychart
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Prev. Close
4.6451
Open
4.9154
High
5.0472
Low
4.627
52 wk Range
4.65-13.02
Market Cap
370 M
P/E Ratio
7.2813
Shares Outstanding
79 477 K
Revenue
412 M
EPS
-0.04
Beta
1.484
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with CorMedix Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CorMedix Inc data using free add-ons & libraries
Get CorMedix Inc Fundamental Data
CorMedix Inc Fundamental data includes:
- Net Revenue: 412 M
- EBITDA: 211 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CorMedix Inc News
New
CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition t Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news ...
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix Therapeutics CRMD reported an adjusted loss of 4 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The company reported adjusted e...
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago. These figures are adj...
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Aurora Cannabis (ACB [https://seekingalpha.com/symbol/ACB]) * On...
Get CorMedix Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.